Cullinan Management EBITDA | CGEM

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Cullinan Management

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-241 M	-197 M	-191 M	145 M	-67.9 M	-60.3 M	-22.2 M	-14.5 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
145 M	-241 M	-81.1 M

Quarterly EBITDA Cullinan Management

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-57.1 M	-53.6 M	-	-	-54.9 M	-	-	-	-42.9 M	-	-	-	-62.7 M	-	-29.7 M	240 M	-32.6 M	-	-18.3 M	-16.6 M	1.39 M	-	-11.5 M	-14.1 M	-5.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
240 M	-62.7 M	-11.3 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	32.3 M	$ 51.0	1.83 %	$ 1.48 B	USA
Allakos ALLK	-115 M	-	-	$ 28.6 M	USA
Black Diamond Therapeutics BDTX	12.8 M	$ 1.88	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	-44.2 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
Evelo Biosciences EVLO	-106 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	489 M	$ 60.26	0.06 %	$ 11.6 B	USA
BioNTech SE BNTX	-1.4 B	$ 98.52	0.24 %	$ 23.8 B	Germany
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 2.17	0.46 %	$ 3.57 M	Israel
Freeline Therapeutics Holdings plc FRLN	-96.7 M	-	-	$ 384 M	Britain
Genocea Biosciences GNCA	-50.5 M	-	-15.0 %	$ 3.04 M	USA
Catalyst Biosciences CBIO	14 M	$ 13.99	0.84 %	$ 1.25 B	USA
C4 Therapeutics CCCC	-113 M	$ 2.98	0.3 %	$ 247 M	USA
Codexis CDXS	-36.5 M	$ 1.32	1.09 %	$ 115 M	USA
Amryt Pharma plc AMYT	-38.6 M	-	-	$ 621 M	Britain
Cerus Corporation CERS	-7.26 M	$ 2.62	0.38 %	$ 499 M	USA
G1 Therapeutics GTHX	-39 M	-	-	$ 370 M	USA
Coherus BioSciences CHRS	-180 M	$ 1.13	0.43 %	$ 132 M	USA
Celldex Therapeutics CLDX	-284 M	$ 31.1	1.16 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	-10.6 M	$ 4.25	3.16 %	$ 51.9 M	Israel
Cellectar Biosciences CLRB	-22.8 M	$ 1.8	0.72 %	$ 4.69 M	USA
AbbVie ABBV	15.8 B	$ 264.34	0.09 %	$ 468 B	USA
Humanigen HGEN	-68.3 M	-	-81.12 %	$ 4.28 M	USA
Cocrystal Pharma COCP	-8.95 M	$ 1.17	1.74 %	$ 13.2 M	USA
AbCellera Biologics ABCL	-199 M	$ 12.7	0.4 %	$ 3.79 B	Canada
Abeona Therapeutics ABEO	-86.9 M	$ 5.4	2.65 %	$ 286 M	USA
Collegium Pharmaceutical COLL	64.9 M	$ 22.53	0.2 %	$ 713 M	USA
Corcept Therapeutics Incorporated CORT	45.9 M	$ 116.1	4.93 %	$ 12.1 B	USA
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
IGM Biosciences IGMS	-199 M	-	-	$ 76.9 M	USA
IMV IMV	-10.9 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	-120 M	-	-	$ 123 M	USA
Cardiff Oncology CRDF	-48.6 M	$ 1.24	0.74 %	$ 82.9 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Corbus Pharmaceuticals Holdings CRBP	-85.1 M	$ 7.14	0.19 %	$ 95.1 M	USA
Karuna Therapeutics KRTX	-493 M	-	-	$ 12.2 B	USA
Curis CRIS	-5.54 M	$ 0.83	1.1 %	$ 10.9 M	USA
CorMedix CRMD	151 M	$ 7.85	1.03 %	$ 565 K	USA
Crinetics Pharmaceuticals CRNX	-513 M	$ 84.95	0.13 %	$ 7.99 B	USA
CRISPR Therapeutics AG CRSP	-645 M	$ 54.23	0.23 %	$ 4.88 B	Schweiz
Champions Oncology CSBR	260 K	$ 4.9	0.1 %	$ 67.8 M	USA
Chimerix CMRX	-96.5 M	-	-	$ 756 M	USA
Corvus Pharmaceuticals CRVS	-42.9 M	$ 11.62	8.21 %	$ 918 M	USA
Cue Biopharma CUE	-25.6 M	$ 31.41	1.45 %	$ 2.98 B	USA
CEL-SCI Corporation CVM	-22.8 M	$ 1.67	2.38 %	$ 13.4 M	USA
Arbutus Biopharma Corporation ABUS	-37.8 M	$ 4.85	0.2 %	$ 929 M	Canada
Cytokinetics, Incorporated CYTK	-602 M	$ 64.66	0.17 %	$ 7.77 M	USA
Daré Bioscience DARE	-11.9 M	$ 0.78	4.73 %	$ 8.72 M	USA
Adagene ADAG	-21 M	$ 2.93	2.86 %	$ 173 M	China
DiaMedica Therapeutics DMAC	-34.4 M	$ 7.94	1.4 %	$ 373 M	USA